AbbVie Inc. (ABBV) Wins FDA Approval For JUVMO In Parkinson's
AbbVie Inc. received U.S. FDA approval for JUVMO (tavapadon) tablets, a selective D1/D5 receptor agonist, for adult Parkinson's disease. The company expects U.S. availability in October 2026.Material DetailsContext by AI AnalystThis is a late-stage milestone converting R&D into a commercial asset i…